Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aztreonam: the first monobactam.

H C Neu1

  • 1Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.

The Medical Clinics of North America
|May 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postantibiotic effect of ceftibuten on respiratory pathogens.

The Pediatric infectious disease journal·1995
Same author

Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.

The Pediatric infectious disease journal·1995
Same author

In vitro activity of SCE-2787, a new cephalosporin with potent activity against Pseudomonas aeruginosa and members of the family Enterobacteriaceae.

Antimicrobial agents and chemotherapy·1994
Same author

Emerging trends in antimicrobial resistance in surgical infections. A review.

The European journal of surgery. Supplement. : = Acta chirurgica. Supplement·1994
Same author

Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Drugs·1993
Same author

Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages.

The Journal of experimental medicine·1992
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Aztreonam offers effective, safe treatment for serious infections caused by multidrug-resistant gram-negative bacteria. It can be used alone or in combination therapy, reducing the need for more toxic agents.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Internal Medicine

Background:

  • Multidrug-resistant (MDR) Gram-negative bacterial infections pose a significant therapeutic challenge.
  • Aztreonam is a monobactam antibiotic with activity against aerobic Gram-negative bacteria.

Purpose of the Study:

  • To evaluate the clinical utility of aztreonam in managing infections caused by MDR Gram-negative pathogens.
  • To determine appropriate dosing strategies and combination therapies involving aztreonam.

Main Methods:

  • Review of clinical data and therapeutic guidelines for aztreonam use.
  • Analysis of aztreonam's spectrum of activity against resistant bacterial strains.
  • Evaluation of treatment outcomes in patients receiving aztreonam for various infections.

Related Experiment Videos

Main Results:

  • Aztreonam demonstrates efficacy as monotherapy for infections caused by susceptible MDR Gram-negative bacteria.
  • It can replace aminoglycosides in combination regimens for mixed infections.
  • Combination with Gram-positive or anaerobic agents is effective for suspected polymicrobial infections.

Conclusions:

  • Aztreonam is a valuable therapeutic option for serious infections due to MDR aerobic Gram-negative bacteria.
  • It is particularly useful in immunocompromised patients when combined with agents targeting Gram-positive organisms.
  • Dosage adjustments are necessary for patients with renal impairment.